The European Commission has now granted conditional approval to Janssen-Cilag's (Johnson & Johnson) first-in-class anti-CD38 antibody Darzalex (daratumumab; licensed form Genmab) for use in melanoma following a CHMP positive opinion in April. (Also see "Accelerated EU Committee Nod for J&J/Genmab's Darzalex " - Scrip, 2 April, 2016.)
The approval, the second for the novel product after it was given an earlier-than-expected go-ahead by the US FDA last...